InsidersTradesSigma
Total declarations
Companies
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Manning Paul B, Director. Director active across 6 companies, notably Taysha Gene Therapies, Inc.. Cumulatively, 20 disclosures have been recorded. Total volume traded: €4.5m. The latest transaction was filed on 31 March 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations20 total
0435,674 shares0
Common Stock
SEC:0001104659-22-047871:0·
€2m392,156 shares@ €4.73020.037% mcap100.0% of flow
Common Stock
SEC:0001104659-22-047360:0·
Ideal exit: 13 Jan 2023 (T+270)
€399,73558,000 shares@ €6.8920.023% mcap26.5% of flow
Common Stock
SEC:0001209191-22-007126:0·
Ideal exit: 30 Oct 2022 (T+270)
€399,73558,000 shares@ €6.8920.023% mcap61.6% of flow
Common Stock
SEC:0001209191-22-007126·
Ideal exit: 30 Oct 2022 (T+270)
€250,64430,023 shares@ €8.3484100.0% of flow
Common Stock
SEC:0001209191-21-068031·
Ideal exit: 29 Aug 2022 (T+270)
€250,64430,023 shares@ €8.34840.23% mcap50.0% of flow
Common Stock
SEC:0001209191-21-068031:0·
Ideal exit: 29 Aug 2022 (T+270)
€25,8292,202 shares@ €11.72974.0% of flow
Common Stock
SEC:0001209191-21-067005·
Ideal exit: 21 Aug 2022 (T+270)
€25,8292,202 shares@ €11.72970.0015% mcap1.7% of flow
Common Stock
SEC:0001209191-21-067005:0·
Ideal exit: 21 Aug 2022 (T+270)
€223,08920,000 shares@ €11.154534.4% of flow
Common Stock
SEC:0001209191-21-066702·
Ideal exit: 20 Aug 2022 (T+270)
€223,08920,000 shares@ €11.15450.013% mcap14.8% of flow
Common Stock
SEC:0001209191-21-066702:0·
Ideal exit: 20 Aug 2022 (T+270)
679,158 shares
Common Stock
SEC:0000899243-21-031614·
679,158 shares
Common Stock
SEC:0000899243-21-031614:0·
679,158 shares
Common Stock
SEC:0000899243-21-031096·
679,158 shares
Common Stock
SEC:0000899243-21-031096:0·
€223,99736,000 shares@ €6.2221100.0% of flow
Common Stock
SEC:0000899243-21-030774·
Ideal exit: 23 Apr 2022 (T+270)
€223,99736,000 shares@ €6.22210.072% mcap50.0% of flow
Common Stock
SEC:0000899243-21-030774:0·
Ideal exit: 23 Apr 2022 (T+270)
2,950,484 shares
Common Stock
SEC:0001209191-21-046042·
2,950,484 shares
Common Stock
SEC:0001209191-21-046042:0·
€208,45712,000 shares@ €17.3714100.0% of flow
Common Stock
SEC:0001209191-21-033009·
Ideal exit: 8 Feb 2022 (T+270)
€208,45712,000 shares@ €17.37140.012% mcap13.8% of flow
Common Stock
SEC:0001209191-21-033009:0·
Ideal exit: 8 Feb 2022 (T+270)
20 of 20 declarations
About Manning Paul B
Manning Paul B is an executive at Taysha Gene Therapies, Inc.
